Bispecific antibodies in cancer therapy, from the laboratory to the clinic

Journal of Immunotherapy

Volumn 22, Issue 6, 1999, Pages 514-524

  Koelemij, Ron ^a   Kuppen, Peter J K ^a   Van De Velde, Cornelis J H ^a   Fleuren, Gert Jan ^a   Hagenaars, Martin ^a   Eggermont, Alexander M M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Animal models; Bispecific monoclonal antibodies; Clinical studies; Review

Indexed keywords

BISPECIFIC ANTIBODY; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; NONHUMAN; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TARGET ORGAN; TUMOR ESCAPE;

EID: 0032700376     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199911000-00006     Document Type: Article

References (109)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
2. Mellstedt H. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1990;2:708-13.
3. Riethmüller G, Schneider-Gädicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993;5:732-9.
4. Grossbard ML, Press OW, Appelbaum FR, et al. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992;80:863-78.
5. Matthews DC, Appelbaum FR, Press OW, et al. Targeted therapy for hematologic malignancies: has its promise been realized? Curr Opin Hematol 1995;2:235-9.
6. Janson CH, Tehrani M, Wigzell H, et al. Rational use of biological response modifiers in hematological malignancies-a review of treatment with interferon, cytotoxic cells and antibodies. Leuk Res 1989;13:1039-46.
7. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 1994;343:1177-83.
8. August DA, Ottow RT, Sugarbaker PH. Clinical perspectives on human colorectal cancer metastasis. Cancer Metastasis Rev 1984; 3:303-24.
9. Gorter A, Blok VT, Haasnoot WH, et al. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis. Lab Invest 1996;74:1039-49.
10. Reynolds JC, Del Vecchio S, Sakahara H. Anti-murine response to mouse monoclonal antibodies: clinical findings and implications. Nucl Med Biol 1989;16:121-5.
11. Seccamani E, Tattanelli M, Mariani M. A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Nucl Med Biol 1989;16:167-70.
12. Lamers CHJ, Gratama JW, Wamaar SO, et al. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer 1995;60: 450-7.
13. Steplewski Z, Sun LK, Shearman CW, et al. Biological activity of human-mouse IgGl, IgG3 and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sei USA 1988; 85:4852-6.
14. Fanger MW, Morganelli PM, Guyre PM. Use of bispecific antibodies in the therapy of tumors. Cancer Treat Res 1993;68: 181-94.
15. Van Dijk J, Warnaar SO, van Eendenburg JDH, et al. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int J Cancer 1989; 43:344-9.
16. Van Ravenswaay Claasen HH, Van de Griend RJ, Mezzanzanica D, et al. Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. Int J Cancer 1993;55:128-36.
17. Küfer P, Mack M, Gruber R, et al. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother 1997;45:193-7.
18. Fleuren GJ, Gorter A, Kuppen PJK, et al. Tumor heterogeneity and immunotherapy of cancer. Immunol Rev 1995;145:91-122.
19. Eisenbach L, Feldman M. Tumor cell surface determinants in host immunity against metastases. Cancer Biol 1991;2:179-88.
20. Hilders CGJM, Houbiers JGA, Krul EJT, et al. The expression of histocompatibility leukocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 1994;101:5-12.
21. Kaklamanis L, Hill A. MHC loss in colorectal tumours: evidence for immunoselection. Cancer Surv 1995;13:155-71.
22. Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys 1961;93:460-2.
23. Hämmerling U, Aoki T, de Harven E, et al. Use of hybrid antibody with anti-gammaG and anti-ferritin specificities in locating cell surface antigens by electron microscopy. J Exp Med 1968; 128:1461-73.
24. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985;314:628-31.
25. Nelson H, Ramsey PS, Kerr LA, et al. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft. J Immunol 1990;145:3507-15.
26. Segal DM, Snider DP. Targeting and activation of cytotoxic lymphocytes. Chem Immunol 1989;47:179-213.
27. Brennan M, Davison PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 1985;229:81-3.
28. 2 antibody containing thioether-linked Fab’gamma fragments. J Immunol 1987;139: 2367-75.
29. Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983;305:537-40.
30. Staerz UD, Bevan MJ. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sei USA 1986;83:1453-7.
31. Milstein C, Cuello AC. Hybrid hybridomas and the production of bi-specific monoclonal antibodies. Immunol Today 1984;5:299-304.
32. Kuppen PJK, Eggermont AMM, Smits KM, et al. The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531. Cancer Immunol Immunother 1993;36:403-8.
33. Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992;148:1547-53.
34. O’Shea EK, Rutkowski R, Stafford W, et al. Preferential heterodimer formation by isolated leucine zippers from Fos and Jun. Science 1989;245:646.
35. Traunecker A, Lanzavecchia A, Karjalainen K. Janusin: new molecular design for bispecific reagents. Int J Cancer 1992;(suppl 7):51-2.
36. Kurucz I, Titus JA, Jost CR, et al. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J Immunol 1995;154:4576-82.
37. Mack M, Gruber R, Schmidt S, et al. Biologic properties of a bispecific single-chain antibody directed against 17-1A (Ep-CAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol 1997;158:3965-70.
38. Holliger P, Winter G. Diabodies: small bispecific antibody fragments. Cancer Immunol Immunother 1997;45:128-30.
39. Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90:6444-8.
40. Staerz UD, Bevan MJ. Use of anti-receptor antibodies to focus T-cell activity. Immunol Today 1986;7:241-5.
41. Perez P, Hoffman RW, Shaw S, et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985;316:354-6.
42. Van Dijk J, Tsuruo T, Segal DM, et al. Bispecific antibodies reactive with the multidrug-resistance-related glycoprotein and CD3 induce lysis of multidrug-resistant tumor cells. Int J Cancer 1989;44:738-43.
43. Beun GDM, Van de Velde CJH, Fleuren GJ. T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: III. Activation of resting T cells and tumor neutralization induced by bispecific antibodies. J Immunother 1993;13:223-31.
44. Van Dijk J, Zegveld ST, Fleuren GJ, et al. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/ G250 in human renal-cell carcinoma xenografts’, relative effects of size and affinity. Int J Cancer 1991;48:738-43.
45. Lanzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 1987;17: 105-11.
46. Titus JA, Perez P, Kaubisch A, et al. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol 1987;139:3153-8.
47. Eisenthal A, Cameron RB, Uppenkamp I, et al. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Res 1988;48:7140-5.
48. Karpovsky B, Titus JA, Stephany DA, et al. Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target and anti-Fcgamma receptor antibodies. J Exp Med 1987;160:1686-701.
49. Ferrini S, Cambiaggi A, Cantoni C, et al. Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules. Int J Cancer 1992; 52(suppl 7):15-8.
50. Lanier LL, Phillips JH. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today 1996;17:86-91.
51. Long EO, Burshtyn DN, Clark WP, et al. Killer cell inhibitory receptors: diversity, specificity, and function. Immunol Rev 1997; 155:135-44.
52. Moretta A, Parolini S, Castriconi R, et al. Function and specificity of human natural killer cell receptors. Eur J Immunogenet 1997; 24:457-68.
53. Beun GDM, Gorter A, Nooyen Y, et al. T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. II. Syngeneic colon carcinoma CC531 is efficiently killed by retargeted cytotoxic T-lymphocytes in vitro despite limited lysis in 51-Cr release assays. J Immunol 1993;150:2305-15.
54. Beun GDM, Van de Velde CJH, Fleuren GJ, et al. T cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model. IV. Tumor neutralization in Winn type assays. J Immunother 1993;14:11-5.
55. 2 antibody prolong host survival in a murine xenograft model. Cancer Res 1991;51:5716-21.
56. Garrido MA, Valdayo MJ, Winkler DF, et al. Targeting of human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice. Cancer Res 1990; 50:4227-32.
57. Van Ravenswaay Claasen HH, Eggermont AMM, Nooyen YA, et al. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC™R. Gynecol Oncol 1994;52:199-206.
58. Weiner GJ. Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice. Int J Cancer 1992; 52(suppl 7):63-6.
59. Demanet C, Brissinck J, Moser M, et al. Bispecific antibody therapy of two murine B-cell lymphomas. Int J Cancer 1992;52(suppl 7):67-8.
60. Takahashi H, Nakada T, Puisieux I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 1993;259:1460-3.
61. June CH, Ledbetter JA, Linsley PS, et al. Role of the CD28 receptor in T-cell activation. Immunol Today 1990;11:211-6.
62. Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-9.
63. Renner C, Pfreundschuh M. Treatment of heterotransplanted Hodgkin’s tumors in SCID mice by a combination of human NK orT cells and bispecific antibodies. J Hematother 1995;4:447-51.
64. Renner C, Bauer S, Sahin U, et al. Cure of disseminated xenografted human Hodgkin’s tumors by bispecific monoclonal antibodies and human T cells: the role of human T cell subsets in a preclinical model. Blood 1995;87:2930-7.
65. Bohlen H, Manzke O, Titzer S, et al. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Cancer Res 1997;57:1704-9.
66. Porter LE, Nelson H, Ethem Gecim I, et al. T cell activation and retargeting using staphylococcal enterotoxin B and bispecific antibody: an effective in vivo antitumor strategy. Cancer Immunol Immunother 1997;45:180-3.
67. Brissinck J, Demanet C, Moser M, et al. Treatment of mice bearing BCLj lymphoma with bispecific antibodies. J Immunol 1991; 147:4019-26.
68. Hagenaars M, Ensink NG, Koelemij R, et al. Regional administration of natural killer cells in a rat hepatic metastasis model results in better tumor infiltration and anti-tumor response than systemic administration. Int J Cancer 1998;75:233-8.
69. Kuppen PJK, Basse PH, Goldfarb RH, et al. The infiltration of experimentally induced lung metastases of colon carcinoma CC531 by adoptively transferred interleukin-2-activated natural killer cells in Wag rats. Int J Cancer 1994;56:574-9.
70. Kroesen BJ, Ter Haar A, Spakman H, et al. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother 1993; 37:400-7.
71. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995;87:1463-9.
72. Bolhuis RLH, Lamers CHJ, Goey SH, et al. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer 1992;52(suppl 7):78-81.
73. Eggermont AMM, Goey SH, Dukel L, et al. Intraperitoneal therapy of ovarian cancer with retargeted lymphocytes by bispecific monoclonal antibodies and interleukin-2. In: Klapdor R, ed. Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties. Munich: W. Zuckschwerdt Verlag, 1993:697-700.
74. Lamers CHJ, Van de Griend RJ, Braakman E, et al. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int J Cancer 1992;51:973-9.
75. Canevari S, Mezzanzanica D, Mazzoni A, et al. Approaches to implement bispecific antibody treatment of ovarian carcinoma. Cancer Immunol Immunother 1997;45:187-9.
76. Lamers CHJ, Bolhuis RLH, Wamaar SO, et al. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody. Int J Cancer 1997;73: 211-9.
77. Nitta T, Sato K, Yagita H, et al. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990;335: 368-71.
78. Weiner LM, Clark JI, Ring DB, et al. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and FcgammaRIII. J Hematother 1995;4:453-6.
79. Weiner LM, Clark JI, Davey M, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c erbB-2 and FcgammaRIII. Cancer Res 1995;55:4586-93.
80. Hartmann F, Renner C, Jung W, et al. Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood 1997;89:2042-7.
81. Kroesen BJ, Buter J, Sleijfer DT, et al. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 1994;70:652-61.
82. Valone FH, Kaufman PA, Guyre PM, et al. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J Hematother 1995;4:471-5.
83. Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995;13:2281-92.
84. De Gast GC, Haagen I-A, Van Houten AA, et al. CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 1995;40:390-6.
85. Bolhuis RLH, Ronteltap CPM, Van Dijk J, Wamaar SO, Braakman E. T cell activation by bispecific monoclonal antibodies for immunotherapy of cancer: fundamental, practical and clinical applications. In: Romet-Lemonne JL, Fanger MW, Segal DM, eds. Bispecific antibodies and targeted cellular cytotoxicity. Les Ulis, France: Fondation Nationale de Transfusion Sanguine, 1990; 227-31.
86. Velders MP, Litvinov SV, Wamaar SO, et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994;54:1753-9.
87. Ollson L, Ebbesen P. Natural polyclonality of spontaneous AKR leukemia and its consequences for so-called specific immunotherapy. J Natl Cancer Inst 1979;62:623-7.
88. Ramesh R, Marrogi AJ, Munshi A, et al. In vivo analysis of the ‘bystander effect’: a cytokine cascade. Exp Hematol 1996;24: 829-38.
89. Arteaga CL, Hurd SD, Winnier AR, et al. Anti-transforming growth factor (TGF)-(3 antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-(3 interactions in human breast cancer progression. J Clin Invest 1993;92:2569-76.
90. McCartney-Francis NL, Wahl SM. Transforming growth factor: a matter of life and death. J Leukocyte Biol 1994;55:401-9.
91. 2 on T cell proliferative response. J Clin Lab Immunol 1989;29:167-73.
92. 2-induced changes in the phenotype, morphology, and lytic activity of IL-2-activated natural killer cells. J Immunol 1993;150:3747-54.
93. Hirte HW, Clark DA, O’Neil G, et al. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-3 in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell Immunol 1992;142:207-16.
94. Sahin U, Kraft-Bauer S, Ohnesorge S, et al. Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors. Cancer Immunol Immunother 1996; 42:9-14.
95. Grabstein KH, Urdal DL, Tushinski RJ, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986;232:506-8.
96. Masucci G, Wersall P, Ragnhammar P, et al. Granulocyte-macrophage colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody dependent cellular cytotoxicity. Cancer Immunol Immunother 1989;29:288-92.
97. Ragnhammar P, Fagerberg J, Frödin J-E, et al. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int J Cancer 1993;53:751-8.
98. Stockmeyer B, Valerius T, Repp R, et al. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 1997;57: 696-701.
99. Repp R, Valerius T, Wieland G, et al. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to FcgammaRI and to HER-2/neu (MDX-210). J Hematother 1995; 4:415-21.
100. van Ojik HH, Repp R, Groenewegen G, et al. Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer. Cancer Immunol Immunother 1997;45:207-9.
101. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86: 10024-8.
102. Brocker T, Peter A, Traunecker A, et al. New simplified molecular design for functional T cell receptor. Eur J Immunol 1993;23: 1435-9.
103. Stancovski I, Schindler DG, Waks T, et al. Targeting of T-lymphocytes to Neu/HER-expressing ceils using chimeric single chain Fv receptors. J Immunol 1993;151:6577-82.
104. Altenschmidt U, Kahl R, Moritz D, et al. Cytolysis of tumor cells expressing the neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 1996; 2:1001-8.
105. Moritz D, Groner B. A spacer region between the single chain antibody and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 1995;2:539-46.
106. Weiner GJ, Hillstrom JR. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 1991; 147: 4035-44.
107. Liu MA, Cho WS, Hawe LA, et al. In vivo evaluation of the antitumor activity of hormone-antibody bifunctional conjugates plus human cytotoxic T lymphocytes. In: Romet-Lemonne JL, Fanger MW, Segal DM, eds. Bispecific antibodies and targeted cellular cytotoxicity. Les Ulis, France: Fondation Nationale de Transfusion Sanguine, 1990:213-7.
108. Kroesen BJ, Helfrich W, Bakker A, et al. Reduction of EGP-2-positive pulmonary métastasés by bispecific-antibody-redirected T cells in an immunocompetent rat model. Int J Cancer 1995;61: 812-8.
109. De Leij L, deJonge M, Terhaar A, et al. Intrapleural and intraperitoneal application of bispecific antibody retargeted lymphocytes to cancer patients. In: Romet-Lemonne JL, Fanger MW, Segal DM, eds. Bispecific antibodies and targeted cellular cytotoxicity. Les Ulis, France: Fondation Nationale de Transfusion Sanguine, 1990:249-53.